Major growth investor Baillie Gifford significantly reduced its stake in Insulet Corp. (PODD) during the third quarter of 2026, cutting its holding by 77.55% from 2.04 million shares down to just under 459,000. Insulet is a medical device company known for its Omnipod system, a tubeless and wearable insulin delivery device for people with diabetes. The firm's position fell from a reported value of $310.94 million to $59.82 million.
This trade information was disclosed in a quarterly 13F filing with the SEC on November 9, 2026, which reflects portfolio changes made during the three-month period ending September 30. The filing reveals a substantial divestment from the diabetes care technology maker, though the specific reasons for the Scottish asset manager's large-scale reduction have not been publicly stated.